Washington, D.C., Jan. 24, 2025 (GLOBE NEWSWIRE) -- The Thurgood Marshall College Fund (TMCF) has received a substantial grant from Lilly Endowment Inc. to increase capacity at the organization and for the historically Black colleges and universities (HBCUs) that are its member schools. The $25 million grant will fund Project HBCU Capacity Building: Maximizing HBCU Performance Through Investments in Research, Operations and Innovation. Through strategic investments and partnerships, TMCF will work to addres ...

Pharmaceutical and Biotech Industry Overview - The pharmaceutical and biotech industry generally offers steady revenue performance due to the essential nature of medicines, but certain companies exhibit growth-like behavior when they innovate rapidly or operate in high-growth areas [1] Eli Lilly - Eli Lilly has experienced significant growth driven by its weight-loss drugs, Zepbound and Mounjaro, which generated $1.2 billion and $3.1 billion in revenue respectively in the most recent quarter [3] - The company is increasing production of these drugs, expecting a 60% rise in doses in the first half of this year compared to the same period last year [4] - Analysts predict the obesity drug market could reach $100 billion to $130 billion by 2030, positioning Eli Lilly for potential long-term stock price gains despite a 200% increase over the past three years [5] Vertex Pharmaceuticals - Vertex Pharmaceuticals is a global leader in cystic fibrosis treatment, with product revenue exceeding $2.7 billion in the recent quarter, driven by its top-selling drug Trikafta [6][7] - The company recently gained FDA approval for Alyftrek, a more efficacious and convenient once-daily cystic fibrosis treatment [6] - Vertex has applied for FDA approval of suzetrigine, a non-opioid candidate for moderate-to-severe acute pain, with a decision expected by the end of January, potentially representing a significant near-term catalyst [8] - If approved, suzetrigine could become a multibillion-dollar drug, offering a major long-term growth opportunity in the pain management market [9] - Vertex's stock has climbed 87% over the past three years, with further growth potential due to its innovative pipeline [10]

INDIANAPOLIS, Jan. 23, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance and guidance. The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be p ...

Stock Performance - Eli Lilly closed at $753 98, marking a +1 57% move from the previous day, outpacing the S&P 500's daily gain of 0 61% [1] - Shares of the company had lost 6 7% over the past month, lagging the Medical sector's gain of 1 64% and the S&P 500's gain of 2 08% [1] Earnings and Revenue Projections - The company is predicted to post an EPS of $5 22, indicating a 109 64% growth compared to the equivalent quarter last year [2] - Revenue is expected to be $13 49 billion, showing a 44 23% escalation compared to the year-ago quarter [2] Analyst Estimates and Zacks Rank - Recent adjustments to analyst estimates reflect the latest near-term business trends, with upbeat changes indicating a favorable outlook on the company's business health and profitability [3] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has an impressive track record, with 1 stocks generating an average annual return of +25% since 1988 [4][5] - Eli Lilly currently possesses a Zacks Rank of 3 (Hold) [5] Valuation Metrics - Eli Lilly has a Forward P/E ratio of 31 3, indicating a premium compared to its industry's Forward P/E of 12 61 [6] - The company has a PEG ratio of 1 56, compared to the industry average of 1 32 [6] Industry Overview - The Large Cap Pharmaceuticals industry is part of the Medical sector and currently holds a Zacks Industry Rank of 207, positioning it in the bottom 18% of all 250+ industries [7] - The Zacks Industry Rank shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Shares of Eli Lilly and Company LLY are trading higher after getting pummeled on Friday. The move lower happened after the company announced preliminary sales that were less than expected. The sales were $45 billion and investors were looking for $46 billion.There's a good chance that the move lower is over. There is also a good chance that the stock is about to rebound. This is why our team of technical analysts and traders has made it our Stock of the Day.As you can see on the chart, there has been suppor ...

On January 14th, Eli Lilly (NYSE: LLY ) released updated revenue guidance for Q4 FY24, with a $400 million reduction from the previously issued forecast. The stock dropped over 8% that day, which, I think, was disproportionate to a small 0.6% reduction in revenue projections.We bring a rigorous research-driven approach to uncovering high-conviction stocks with compelling growth potential across dynamic sectors like big tech, semiconductors, AI, and healthcare. Leveraging comprehensive sector insights, We an ...

Highly coveted weight-loss related diabetes drugs produced by Danish drugmaker Novo Nordisk are among the medications that will be subject to price controls by Medicare. On Friday, the Centers for Medicare & Medicaid Services (CMS) released the second list of prescription medications covered under Medicare Part D. The list has 15 drugs, touted as an effort to help lower the financial burden for millions of patients who are 65 years and older. It includes Novo Nordisk's weight loss and diabetes drugs Wegovy ...

Eli Lilly's Market Performance - Eli Lilly became the world's largest healthcare company with a market cap exceeding $860 billion during its nearly four-year run starting in late 2020 [1] - The company's stock has significantly pulled back over the last eight weeks, including a recent sell-off after cutting its 2024 revenue guidance due to lower-than-expected demand for its obesity and diabetes drugs [2] Trump's Tariff Policies - Trump proposed tariffs of at least 10% and up to 20% on all imports, with higher rates for specific countries like Canada (25%), Mexico (25%), and China (60%) [3][4][5] - The president-elect plans to create an "External Revenue Service" to collect tariffs, a responsibility currently handled by U S Customs and Border Protection [4] - Tariffs typically lead to higher prices for imported products, with costs usually passed on to consumers [6] Impact on Novo Nordisk and Eli Lilly - Novo Nordisk, based in Denmark, faces potential high tariffs under Trump's policies, which could increase prices for its drugs Ozempic and Wegovy [7][8] - Novo Nordisk's management expressed concern but did not comment on potential price impacts, stating they remain focused on delivering medicines [9] - Higher prices for Ozempic and Wegovy could benefit Eli Lilly by increasing demand for its competing drugs Mounjaro and Zepbound, especially if insurers favor Lilly's products to reduce costs [10] Future Outlook for Eli Lilly - Eli Lilly's sales for Mounjaro and Zepbound are expected to continue growing, with potential new product launches like the obesity drug orforglipron in early 2026 and the Alzheimer's drug Kisunla gaining momentum [13] - While Trump's tariffs may or may not make Eli Lilly a no-brainer stock in 2025, the company remains a strong investment regardless of political developments [13]

Health & FitnessWATCH: 1st Drug Approved For Sleep Apnea Patients The head of LI-based sleep disorders centers talks about the weight-loss drug Zepbound, now approved to treat obstructive sleep apnea. A Long Island doctor talks about the FDA approving a weight-loss drug for sleep apnea. (Jerry Barmash/Patch)VALLEY STREAM, NY — The FDA announced the approval last month of the first drug for patients suffering from obstructive sleep apnea."This medicine is just another in our arsenal of tools that we can use, ...

Eli Lilly and Company (LLY) announced that the FDA has granted approval to its drug, Omvoh (mirikizumab), for its second inflammatory bowel disease (IBD) condition, Crohn's disease (“CD”), in the United States. Omvoh was approved for its first IBD indication, moderately to severely active ulcerative colitis (“UC”), in 2023. The drug is currently approved for UC in 44 countries.The approval of Omvoh for moderately to severely active CD in adults was based on data from the VIVID 1 study. The study met both it ...